睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌II/III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07490262,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed hepatocellular carcinoma (HCC).

    入选标准第 1 条

  3. Child-Pugh score ≤7.

    入选标准第 7 条

    Symptomatic congestive heart failure (New York Heart Association [NYHA] Class II-IV); symptomatic or inadequately controlled arrhythmias; history of congenital long QT syndrome; or baseline corrected QT interval (QTcF, calculated using Fridericia's formula) >500 ms.

    排除标准第 14 条

  4. Female participants of childbearing potential, or male participants whose sexual partners are of childbearing potential, must use effective contraception throughout the treatment period and for 15 months after the last dose of oxaliplatin (for females) / 12 months after the last dose of oxaliplatin (for males), or for 6 months after the last dose of any other investigational drug-whichever period ends later.

    入选标准第 10 条

    Persistent treatment-related toxicities from prior anticancer therapy not resolved to Grade 0 or Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 at the time of randomization.

    排除标准第 13 条

    Prior radiotherapy within 3 weeks before randomization.

    排除标准第 17 条

    Prior treatment with any anti-PD-1, anti-PD-L1/L2, anti-CTLA-4 antibodies, or other immune checkpoint inhibitors.

    排除标准第 30 条

  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.

    入选标准第 3 条

  6. Use of aspirin (>325 mg/day) or other known platelet-function-inhibiting agents (e.g., dipyridamole or clopidogrel) for therapeutic purposes within 10 days prior to randomization. Prophylactic use of anticoagulants is permitted.

    排除标准第 11 条

  7. At screening, per RECIST 1.1, there must be at least one measurable lesion that has not undergone local therapy, or a measurable lesion that has clearly progressed following local therapy (per RECIST 1.1).

    入选标准第 6 条

  8. Histologically or cytologically confirmed diagnosis of fibrolamellar hepatocellular carcinoma (HCC), sarcomatoid HCC, cholangiocarcinoma, or other mixed hepatic malignancies containing these components.

    排除标准第 1 条

    Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection:

    排除标准第 4 条

    Known human immunodeficiency virus (HIV) infection (positive HIV-1/2 antibody test).

    排除标准第 20 条

    Diagnosis of another primary malignancy within 5 years prior to randomization.

    排除标准第 29 条

  9. Female participants who are pregnant or breastfeeding.

    排除标准第 33 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07490262,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Histologically or cytologically confirmed hepatocellular carcinoma (HCC).
  2. Age ≥18 years and ≤75 years.
  3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
  4. Barcelona Clinic Liver Cancer (BCLC) staging of Stage C, or Stage B that is unsuitable for curative-intent surgery and/or locoregional therapy.
  5. No prior systemic antineoplastic therapy for HCC before first dose.
  6. At screening, per RECIST 1.1, there must be at least one measurable lesion that has not undergone local therapy, or a measurable lesion that has clearly progressed following local therapy (per RECIST 1.1).
  7. Child-Pugh score ≤7.
  8. Adequate organ and bone marrow function.
  9. Expected survival ≥12 weeks at the time of treatment initiation.
  10. Female participants of childbearing potential, or male participants whose sexual partners are of childbearing potential, must use effective contraception throughout the treatment period and for 15 months after the last dose of oxaliplatin (for females) / 12 months after the last dose of oxaliplatin (for males), or for 6 months after the last dose of any other investigational drug-whichever period ends later.
  11. Signed written informed consent form, and ability to comply with scheduled visits and all protocol-specified procedures.

排除标准:Exclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of fibrolamellar hepatocellular carcinoma (HCC), sarcomatoid HCC, cholangiocarcinoma, or other mixed hepatic malignancies containing these components.
  2. History of hepatic encephalopathy or prior liver transplantation.
  3. Clinically symptomatic pleural effusion, ascites, or pericardial effusion requiring therapeutic drainage; participants with only minimal (radiologically detected), asymptomatic effusions may be enrolled.
  4. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection:
  5. Known central nervous system (CNS) metastases or symptomatic spinal cord compression.
  6. Esophageal or gastric variceal bleeding due to portal hypertension within the past 6 months; Grade 3 (G3) esophageal/gastric varices documented by endoscopy within 3 months prior to first dose; or evidence of portal hypertension.
  7. Life-threatening hemorrhagic event within the past 3 months, including but not limited to events requiring blood transfusion, surgical or local intervention, or ongoing pharmacologic hemostatic therapy.
  8. Metastatic lesions invading major vessels, airways, or the mediastinum with clinically significant bleeding risk.
  9. Arterial or venous thromboembolic event within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident (stroke), transient ischemic attack (TIA), pulmonary embolism, deep vein thrombosis, or other severe thromboembolic conditions.
  10. Portal vein tumor thrombus (PVTT) involving both the main portal vein and left/right branch; PVTT extending into the superior mesenteric vein; or PVTT involving the inferior vena cava.
  11. Use of aspirin (>325 mg/day) or other known platelet-function-inhibiting agents (e.g., dipyridamole or clopidogrel) for therapeutic purposes within 10 days prior to randomization. Prophylactic use of anticoagulants is permitted.
  12. Uncontrolled hypertension: systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg despite optimal medical management; history of hypertensive crisis or hypertensive encephalopathy.
  13. Persistent treatment-related toxicities from prior anticancer therapy not resolved to Grade 0 or Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 at the time of randomization.
  14. Symptomatic congestive heart failure (New York Heart Association [NYHA] Class II-IV); symptomatic or inadequately controlled arrhythmias; history of congenital long QT syndrome; or baseline corrected QT interval (QTcF, calculated using Fridericia's formula) >500 ms.
  15. Severe bleeding diathesis or coagulopathy; or current thrombolytic therapy.
  16. History of gastrointestinal perforation and/or fistula within the past 6 months; unresolved intestinal obstruction (including incomplete obstruction requiring parenteral nutrition); extensive bowel resection (e.g., partial colectomy or extensive small bowel resection leading to chronic diarrhea); Crohn's disease; ulcerative colitis; or chronic diarrhea of prolonged duration.
  17. Prior radiotherapy within 3 weeks before randomization.
  18. Clinically significant pre-existing pulmonary disease.
  19. Active tuberculosis (TB), currently receiving anti-TB therapy, or having completed anti-TB therapy within the past year.
  20. Known human immunodeficiency virus (HIV) infection (positive HIV-1/2 antibody test).
  21. Active or inadequately controlled severe infection.
  22. Known or suspected active autoimmune disease, or history of active autoimmune disease within the past 2 years.
  23. Systemic immunosuppressive therapy within 2 weeks prior to randomization.
  24. Receipt of live attenuated vaccines within 4 weeks prior to randomization, or planned administration during the study.
  25. Major surgery (e.g., craniotomy, thoracotomy, laparotomy) or presence of unhealed wounds, ulcers, or fractures within 4 weeks prior to randomization.
  26. Local therapy for HCC within 4 weeks prior to first dose.
  27. Use of Traditional Chinese Medicine (TCM) with antitumor indications, or immunomodulatory agents (e.g., thymosin, interferons, interleukins), within 2 weeks prior to first dose.
  28. Uncontrolled or uncorrectable metabolic disorders, non-malignant organ dysfunction, systemic illness, or cancer-related paraneoplastic syndromes posing substantial medical risk or introducing uncertainty in survival assessment - as determined by the investigator; or any other condition deemed unsuitable for enrollment by the investigator.
  29. Diagnosis of another primary malignancy within 5 years prior to randomization.
  30. Prior treatment with any anti-PD-1, anti-PD-L1/L2, anti-CTLA-4 antibodies, or other immune checkpoint inhibitors.
  31. Known hypersensitivity to any active ingredient or excipient of the investigational product; or history of severe allergic reaction (e.g., anaphylaxis) to other monoclonal antibodies.
  32. Receipt of treatment in another interventional clinical trial within 4 weeks prior to randomization.
  33. Female participants who are pregnant or breastfeeding.
  34. Any other acute or chronic medical condition, psychiatric disorder, or clinically significant laboratory abnormality that, in the Investigator's judgment: increases the risks associated with participation in the study or administration of the investigational product; or may interfere with the interpretation of study results - rendering the participant unsuitable for enrollment.

引自 ClinicalTrials.gov, NCT07490262, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07490262,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07490262